News

BioIVT, a leading provider of biospecimens, research models, and services for drug and diagnostic development, today announced its scientific contributions to the 2023 Society of Toxicology (SOT) 62nd Annual Meeting and ToxExpo. This year’s conference will be held from March 19-23 at the Nashville Music City Center in Nashville, TN.

CN Bio appoints Deepak Singh as Vice President of Sales and Marketing


Key appointment as company seeks to continue global expansion of microphysiological systems and contract research service offerings

Leading Scientists Discuss 3D Organoid Culture Research


AMSBIO has interviewed two extraordinary women in the 3D Cell Culture and Organoid field; Dr Hynda Kleinman, one of the co-inventors of Matrigel, and Dr Meritxell Huch, a director at the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) to mark International Women’s Day on the 8th March, and World Organoid Research Day on 22nd March 2023.

ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has announced three senior appointments to its newly incorporated subsidiary company, Inaphaea BioLabs (Inaphaea).


Headquartered in MediCity Nottingham, Inaphaea will offer a wide range of pre-clinical and drug discovery testing services to academic, biotech and pharmaceutical researchers, forming the foundation of ValiRx’s tCRO™ (translational Contract Research Organisation) strategy.

AMSBIO has published an interview with Professor Ryuji Morizane, a renowned expert in renal research at Harvard Medical School. In his award-winning research*, Professor Morizane has successfully combined organoid and bioengineering technology to create kidney organoids that incorporate a vascular structure.

CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System



  • PhysioMimix HT System increases productivity, cost-effectiveness and data robustness

  • Developed to enable earlier adoption of predictive human liver Organ-on-a-Chip models in drug discovery workflows

  • New PhysioMimix multi-chip consumable plate containing 48 liver chips also launched


 

Check out your monthly round up of employee engagement opportunities in this month's People Pathways newsletter! 


NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme


Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s.

Pages